The results of bronchodilator therapy in chronic obstructive pulmonary disease (COPD) are not satisfactory and because of this, many drugs are administered for treatment of disease. We examined the short-term additive bronchodilator effects of tiotropium in patients with stable COPD already treated with salmeterol twice daily. Materials and Methods : in a double-blind, double-dummy randomized study we evaluated the acute bronchodilator efficacy of a single 18 µg dose of tiotropium in patients with COPD under chronic treatment with a long acting beta-adrenergic (salmeterol 50µg twice a day). Measurements of forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1) and six-minute walking test (6 MWT) as indicator of daily activities were made before and after giving the drug. A total of 129 outpatients with stable COPD (Gold level 2 -3-4) were enrolled and 92 completed the study. Results: Tiotropium elicited a significantly greater bronchodilation than the placebo. The action of the drug was elicited as increase in FEV1 (p≤0.001) and FVC (p≤0.001); 6-MWT increased 35 meters in patients treated with tiotropium compared to 2.5 meters in those receiving placebo (p≤0.001). Conclusion: Addition of tiotropium to chronic administration of a betaadrenergic drug such as salmeterol induced an increase in pulmonary function parameters and in exercise capacity suggesting that association of the two drugs can be more efficient for treatment of disease and improvement of daily living activities than beta-adrenergics alone.
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a progressive respiratory disease that can be defined as a pathologic illness characterized by a progressive reduction of respiratory function (1) . The flow-limitation of COPD is due to the reduction of the calibre of the respiratory airways caused by the contraction of smooth bronchial muscles and by the reduction of pulmonary elasticity leading to pulmonary hyperinflation (2) . 
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Tanaffos 2012; 11 (1) : [26] [27] [28] [29] [30] [31] Pharmacological therapy can actually reduce dyspnea and improve exercise tolerance (5) . In addition to betaadrenergic drugs, newer anticholinergic drugs have been recently introduced. These drugs block muscarinic receptors for acetylcholine in the airways, and thus produce a reduction in vagal tone (3).
Five subtypes of human muscarinic receptors have been discovered (from M1 to M5), but in the airways only three subtypes appear (M1, M2, M3). M1 and M3 receptors are stimulated by acetylcholine with the cholinergic effect of bronchoconstriction, while M2 receptors inhibit the release of acetylcholine producing an inhibitory feedback on bronchoconstriction (3). Tiotropium is a potent and highly specific competitive antagonist especially for M1
and M3 receptors (6) . Based on several studies it appears that in patients with COPD tiotropium can significantly reduce the level of dyspnea (7), improve the quality of life (7), and improve the parameters of hyperinflation such as IC, FRC, RV (8) and exercise tolerance (9) . Several short and long term studies on tiotropium have shown an improvement in respiratory function tests greater than with ipratropium (10) or with salmeterol twice daily (11) .
Some studies have recently been published, showing the possibility of augmenting the bronchodilator efficacy in patients with COPD by using the combination of tiotropium with a long-acting beta-adrenergic such as salmeterol (12) or formoterol (13, 14) .The effects observed were faster and greater using the combination of two drugs instead of tiotropium only . We examined the shortterm additive bronchodilator effects of tiotropium in patients with stable COPD already treated with salmeterol twice daily. The characteristics and the subdivision of patients are illustrated in Table 1 and the patients' flow-chart in figure   1 .
MATERIALS AND METHODS
The study was carried out according to the rules of the "Declaration of Helsinki"; the local ethics committee approved our study. All patients provided written informed consent before beginning the study. All treatments were administered at the same time (between 8 and 9 a.m.).
Consumption of cola drinks, coffee or tea was avoided 6 hours before administering the drug and during the investigation.
c) Functional measurements
On test day measurements of FVC, FEV1 and Tiffeneau index ( T.I.) were recorded one hour before and one hour after administering the drug. Spirometric examinations were conducted three times (according to ERS/ATS standard) (16) and the results of the best FVC and FEV1 of three exams were considered in the subsequent analysis.
For the measurements we used Cosmed PFT 4 spirometer (Rome, Italy).
A six minute walk test (according to ATS guidelines) (17) was performed one hour before and one hour after the administration of drug. At the beginning and at the end of each six minute walk test the degree of dyspnea (Borg scale), pulse, respiratory rate and SpO 2 were determined.
d) Statistical analysis
Spirometric data (FVC, FEV1 and TI) and the 6 MWT results were analyzed using the Student's t-test for paired variables. A probability level of p ≤ 0.05 was considered significant for all tests.
RESULTS
One hundred twenty-nine patients were enrolled and 100 were randomized .Twenty-nine patients were excluded because of concurrent cardiovascular disease. These two different mechanisms of action (18), both are associated with improvement of dyspnea, functional parameters, exercise tolerance and quality of life (8, 11, 15) .
A recent paper has revised the idea of reversibility in COPD (19) . An average increase in Our study aimed to reproduce real-life conditions and was done to determine whether or not a short-term functional improvement (an increase in patients' ability to perform activities of daily living) obtained by adding tiotropium is superior to the use of salmeterol alone.
The obtained results, increased FEV1 (≥ 120 ml) and FVC (≥ 170 ml), demonstrate that an inhalation of a single dose of 18 µg of tiotropium produces an improvement in expiratory volume and a reduction in hyperinflation (19, 20) over and above that produced by salmeterol alone. In addition, there was a significant improvement in distance covered during the six-minute walk test.
In conclusion, this study demonstrates that adding tiotropium to salmeterol produces not only a greater bronchodilation than placebo in patients previously treated with a beta-adrenergic drug alone, as suggested by previous authors (22) (23) (24) , but also improves exercise tolerance and the ability to perform morning daily living activities.
